Literature DB >> 20667018

Numerous FUS-positive inclusions in an elderly woman with motor neuron disease.

Yukio Fujita1, Sayaka Fujita, Masamitsu Takatama, Masaki Ikeda, Koichi Okamoto.   

Abstract

We report an autopsy case of a 75-year-old Japanese woman with motor neuron disease (MND) showing numerous neuronal and glial inclusions immunostained with anti-fused in sarcoma (FUS) antibody. At 73 years, she received a diagnosis of MND and died of respiratory insufficiency 2 years later. No mutation was found in all exons of the FUS gene. Neuropathological examination revealed a reduced number of anterior horn cells and degeneration of the pyramidal tracts. Neither Bunina bodies nor inclusions positive for ubiquitin/phosphorylated TAR DNA binding protein of 43 kD (pTDP-43), such as skein-like or round inclusions, were observed. However, basophilic inclusions (BIs) were frequently observed in the remaining neurons of the anterior horns, facial nuclei, hypoglossal nuclei, vestibular nuclei, dentate nuclei and inferior olivary nuclei. In an immunohistochemical analysis, the BIs showed strong immunoreactivity with anti-FUS and anti-ubiquitin-binding protein p62 (p62) antibodies. The nuclear staining of FUS was preserved in some neurons with FUS-positive inclusions, and a few FUS-positive glial inclusions were found. FUS-positive inclusions were more common than p62-positive inclusions in some anatomical regions, and in some neurons, p62 immunoreactivity was observed in only parts of the BIs. These results suggest that BI formation and TDP-43 aggregation have different pathogenic mechanisms, and FUS may play an important role in the pathogenesis of MND with BIs. This patient has the oldest reported age of onset for MND with BIs, and clinical features observed in this patient were indistinguishable from those of classic sporadic MND. Therefore, we consider that the age of onset and clinical features of FUS-related disorders may be variable.
© 2010 Japanese Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20667018     DOI: 10.1111/j.1440-1789.2010.01146.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  9 in total

1.  Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation.

Authors:  Ian R A Mackenzie; Olaf Ansorge; Michael Strong; Juan Bilbao; Lorne Zinman; Lee-Cyn Ang; Matt Baker; Heather Stewart; Andrew Eisen; Rosa Rademakers; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2011-05-21       Impact factor: 17.088

Review 2.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 3.  Fused in Sarcoma Neuropathology in Neurodegenerative Disease.

Authors:  Ian R A Mackenzie; Manuela Neumann
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

4.  Expression of human FUS protein in Drosophila leads to progressive neurodegeneration.

Authors:  Yanbo Chen; Mengxue Yang; Jianwen Deng; Xiaoping Chen; Ye Ye; Li Zhu; Jianghong Liu; Haihong Ye; Yan Shen; Yan Li; Elizabeth J Rao; Kazuo Fushimi; Xiaohong Zhou; Eileen H Bigio; Marsel Mesulam; Qi Xu; Jane Y Wu
Journal:  Protein Cell       Date:  2011-07-12       Impact factor: 14.870

5.  Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.

Authors:  Leeanne McGurk; Virginia M Lee; John Q Trojanowksi; Vivianna M Van Deerlin; Edward B Lee; Nancy M Bonini
Journal:  J Neuropathol Exp Neurol       Date:  2014-09       Impact factor: 3.685

Review 6.  Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.

Authors:  Ian R A Mackenzie; Manuela Neumann; Nigel J Cairns; David G Munoz; Adrian M Isaacs
Journal:  J Mol Neurosci       Date:  2011-05-21       Impact factor: 3.444

7.  Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U.

Authors:  Edward B Lee; Jenny Russ; Hyunjoo Jung; Lauren B Elman; Lama M Chahine; Daniel Kremens; Bruce L Miller; H Branch Coslett; John Q Trojanowski; Vivianna M Van Deerlin; Leo F McCluskey
Journal:  Acta Neuropathol Commun       Date:  2013-05-09       Impact factor: 7.801

Review 8.  Amyotrophic lateral sclerosis: applications of stem cells - an update.

Authors:  Lidia Cova; Vincenzo Silani
Journal:  Stem Cells Cloning       Date:  2010-10-27

Review 9.  Does ALS-FUS without FUS mutation represent ALS-FET? Report of three cases.

Authors:  S Borrego-Écija; E Cortés-Vicente; L Cervera-Carles; J Clarimón; J Gámez; J Batlle; G Ricken; L Molina-Porcel; I Aldecoa; R Sánchez-Valle; R Rojas-García; E Gelpi
Journal:  Neuropathol Appl Neurobiol       Date:  2018-11-20       Impact factor: 8.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.